The chairs of WCLC 2023 say this year’s program offers something for everyone, including practice-changing clinical trial data and innovative basic science as well as presentations to address broader needs within the profession. Read more
Whether you are attending in-person or virtually, the conference app will help you navigate the meeting and connect with your colleagues from around the globe. Read more
Before you pack your bags, make sure you know everything you will need to get to the 2023 World Conference on Lung Cancer without delay. Read more
As you plan your WCLC 2023 itinerary, don’t miss an important session on your list because you don’t have a ticket. Review the ticketed events schedule and be sure you have any tickets you will need. Read more
IASLC Hot Topic meeting to feature keynote address on resistance to immunotherapy by Dr. Drew Pardoll. Lung Cancer Research Foundation announces appointment of new executive director Aubrey Rhodes. Read more
Dr. Quincy Chu recently shared results from the phase III IND227 trial, which also demonstrated improved progression-free survival in mesothelioma patients who received the combination compared to those who received standard chemotherapy alone. Read more
In stage II-IIIA NSCLC patients with high PD-L1 expression, the benefits of atezolizumab and platinum-based chemotherapy after surgical resection appeared to be most prominent in the lobectomy subgroup according to Dr. Alessandro Brunelli and colleagues. Read more
Investigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
Dr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more
During ASCO’s 2023 Annual Meeting investigators shared findings from several neoadjuvant studies, including KEYNOTE-671 and Neotorch, which showed improved EFS with pembrolizumab and toripalimab, respectively. Read more